KEI and UACT comments on the prospective grant of exclusive licenses to Sinotau and MTTI

On August 27, 2018, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) filed comments to the NIH regarding the prospective grant of two separate exclusive licenses to Sinotau Pharmaceutical Group and Molecular Targeting Technologies, Inc. (MTTI),… Continue Reading

Joint Comments by KEI, UACT, Social Security Watch and Health Gap on the proposed NIH Exclusive License in CAR Therapy to Lyell Immunopharma

On September 19, 2019, Knowledge Ecology International (KEI), Union for Affordable Cancer Treatment (UACT), Social Security Works (SSW), Health GAP, and Brook Baker submitted comments regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of CD19/CD22 Chimeric… Continue Reading

Joint Comments Regarding NIH Proposed Exclusive License to Intima Biosciences for Cancer Therapy

On September 13, 2019, Knowledge Ecology International (KEI), Union for Affordable Cancer Treatment (UACT), Public Citizen (PC), Social Security Works (SSW), LWC Health, Ruth Lopert, Manon Ress, and Terry Love submitted comments regarding the “Prospective Grant of an Exclusive Patent… Continue Reading

KEI Request Re: Failure to Disclose Federal Funding in UPenn Bennett et al Patents for Gene Therapy to Treat Blindness

On September 9, 2019, KEI submitted a second request to the NIH that it investigate an apparent failure to disclose federal funding in patents in adeno-associated viral (AAV) gene therapies assigned to the Trustees of the University of Pennsylvania (UPenn).… Continue Reading

KEI, UACT, UAEM, and SSW Appeal NIH Grant of Exclusive Licenses on CAR Cancer Therapy to Gilead/Kite

On September 12, 2019, Knowledge Ecology International (KEI), Union for Affordable Cancer Treatment (UACT), Universities Allied for Essential Medicines (UAEM), Social Security Works (SSW), and Clare Love filed an appeal with the National Institutes of Health (NIH). The signatories appealed… Continue Reading

Zolgensma

Zolgensma is a gene therapy for spinal muscular atrophy (SMA) that was approved by the US FDA in May 2019, at a price of $2.1 million per patient. Zolgensma was licensed from a children’s hospital where it was developed on… Continue Reading

KEI Comments on NIH Exclusive Licenses for CAR T Technologies to Kite/Gilead

On Monday July 29, 2019, Knowledge Ecology International (KEI) submitted joint comments to the NIH on behalf of KEI, Social Security Works (SSW), Universities Allied for Essential Medicines (UAEM), Union for Affordable Cancer Treatment (UACT), and Clare Love, a cancer… Continue Reading